Dexmedetomidine

ID: dexmedetomidine

Aliases: Precedex

Type: compound

Route/form: IV in approved sedation context

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: label, systematic_review

Linked sources: 2

Broad outcomes: Brain / mood / sleep, Pain / addiction / acute care

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• alpha-2 adrenergic agonist

Optimization domains

• sedation
• ICU
• anxiolysis

Research basis

• Clinically important sedative with anxiolytic/sympatholytic profile and less respiratory depression than many sedatives.
• Useful anchor for alpha-2 agonist discussions.

Limits, risks, and missing evidence

• Bradycardia and hypotension are central risks.
• ICU/anesthesia pharmacology does not translate to unsupervised anxiety management.

Risk flags

• prescription
• sedation
• bradycardia
• hypotension

Linked papers, labels, and reviews

1. Alpha-2 agonists for sedation of mechanically ventilated adults
   systematic_review / pubmed_dexmedetomidine_systematic_review
   Includes dexmedetomidine efficacy and bradycardia signal.
2. DailyMed label: dexmedetomidine hydrochloride injection
   label / dailymed_dexmedetomidine_label
   Official IV sedation label; useful for route, indication, bradycardia/hypotension, and interaction framing.